Acute Respiratory Distress Syndrome Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Veru, Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian

The Key Acute Respiratory Distress Syndrome Companies: Veru, Edesa Biotech/Light Chain Bio, Direct Biologics, Healios/Nobel Pharma, Mesoblast, Chrysalis BioTherapeutics, Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeutics, Meridigen Biotech Co., Ltd., Sage Therapeutics, Healios K.K., Chiesi Farmaceutici, Bayer, Altor BioScience, Faron Pharmaceuticals Ltd, AVM Biotechnology, and others.
DelveInsight's "Acute Respiratory Distress Syndrome Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Acute Respiratory Distress Syndrome, historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Acute Respiratory Distress Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acute Respiratory Distress Syndrome Market Forecast [https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Acute Respiratory Distress Syndrome Market Report:

*
The Acute Respiratory Distress Syndrome market size was valued approximately ~USD 1,643 Million in 2023 and is anticipated to grow with a significant CAGR of 3.6 % during the study period (2020-2034)

*
In August 2024, MediciNova was granted a Notice of Allowance by the US Patent and Trademark Office for a pending patent application concerning MN-166 (ibudilast) for post-COVID conditions.

*
Current treatment approaches for Acute Respiratory Distress Syndrome (ARDS) primarily involve Neuromuscular Blockades, Inhaled Vasodilators, Corticosteroids, and other therapies. In 2023, Inhaled Vasodilators held the largest market share, valued at approximately USD 1,063 million across the 7MM for ARDS treatment.

*
In 2023, Germany had the largest market size for Acute Respiratory Distress Syndrome (ARDS) in Europe, reaching approximately USD 206 million, while Spain recorded the smallest market size with around USD 29 million.

*
In 2023, the market size for Acute Respiratory Distress Syndrome (ARDS) in Japan was estimated at approximately USD 46 million, representing 3% of the total market across the 7MM.

*
In 2023, there were approximately 591 thousand new cases of Acute Respiratory Distress Syndrome (ARDS) in the United States.

*
In 2023, the United States represented the largest share of incident cases of Acute Respiratory Distress Syndrome (ARDS), accounting for approximately 62% of the 7MM. Meanwhile, the EU4 and the UK contributed around 34%, and Japan accounted for about 4% of the total population share.

*
In 2023, Germany recorded the highest number of incident cases of Acute Respiratory Distress Syndrome (ARDS) among the EU4 countries, with 181 thousand cases, followed by France with 47 thousand cases. Spain had the lowest number, with 25 thousand cases.

*
In 2023, it was estimated that the United States had approximately 177 thousand incident cases of mild severity, 276 thousand cases of moderate severity, and 138 thousand cases of severe severity.

*
DelveInsight estimates that in 2023, among the risk factor-associated cases of ARDS in the US, there were approximately 210,560 cases of pneumonia, 175,076 cases of sepsis, 18,169 cases of trauma, 61,157 cases of aspiration, 8,974 cases of pancreatitis, 4,757 cases of COVID-19, 63,242 cases of other types, and about 49,340 cases with unknown causes.

*
Key Acute Respiratory Distress Syndrome Companies: Veru, Edesa Biotech/Light Chain Bio, Direct Biologics, Healios/Nobel Pharma, Mesoblast, Chrysalis BioTherapeutics, Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeutics, Meridigen Biotech Co., Ltd., Sage Therapeutics, Healios K.K., Chiesi Farmaceutici, Bayer, Altor BioScience, Faron Pharmaceuticals Ltd, AVM Biotechnology LLC, Amyndas Pharmaceuticals S.A., Kinevant Sciences GmbH, Eli Lilly and Company, Suntory Pharmaceutical, Alexion Pharmaceuticals, Laboratoire francais de Fractionnement et de Biotechnologies (LFB), Evgen Pharma, Dimerix Bioscience, Mylan, Vanda Pharmaceuticals, Kiniksa Pharmaceuticals Foresee Pharmaceuticals, Boehringer Ingelheim, Staidson (Beijing) Biopharmaceuticals, Biohaven Pharmaceuticals, Chimerix, Edesa Biotech, and others

*
Key Acute Respiratory Distress Syndrome Therapies: Sabizabulin (Veru-111), EB05 (paridiprubart), ExoFlo (DB-001), MultiStem (HLCM051), Remestemcel-L, TP508, Traumakine, BIO-11006, MultiStem, Solnatide, VERU-111, Tradipitant, FP-025, HLCM051(MultiStem), and others

*
The Acute Respiratory Distress Syndrome epidemiology based on gender analyze that the percentage of cases of Acute Respiratory Distress Syndrome (ARDS) are equal in both the genders

*
The Acute Respiratory Distress Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Respiratory Distress Syndrome pipeline products will significantly revolutionize the Acute Respiratory Distress Syndrome market dynamics.

Acute Respiratory Distress Syndrome Overview

Acute Respiratory Distress Syndrome (ARDS) is a severe lung condition that causes widespread inflammation and fluid buildup in the lungs, leading to difficulty breathing. It results from various causes such as pneumonia, trauma, sepsis, aspiration, or COVID-19. ARDS can lead to low oxygen levels in the blood, respiratory failure, and may require mechanical ventilation for the patient to breathe. The condition can progress rapidly and is often life-threatening, particularly in critically ill individuals. Treatment typically focuses on supporting breathing, managing the underlying cause, and preventing complications.

Get a Free sample for the Acute Respiratory Distress Syndrome Market Report:

https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market [https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Acute Respiratory Distress Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Acute Respiratory Distress Syndrome Epidemiology Segmentation:

The Acute Respiratory Distress Syndrome market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Acute Respiratory Distress Syndrome

*
Prevalent Cases of Acute Respiratory Distress Syndrome by severity

*
Gender-specific Prevalence of Acute Respiratory Distress Syndrome

*
Diagnosed Cases of Episodic and Chronic Acute Respiratory Distress Syndrome

Download the report to understand which factors are driving Acute Respiratory Distress Syndrome epidemiology trends @ Acute Respiratory Distress Syndrome Epidemiology Forecast [https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Acute Respiratory Distress Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Respiratory Distress Syndrome market or expected to get launched during the study period. The analysis covers Acute Respiratory Distress Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Acute Respiratory Distress Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Acute Respiratory Distress Syndrome Therapies and Key Companies

*
Sabizabulin (Veru-111): Veru

*
EB05 (paridiprubart): Edesa Biotech/Light Chain Bio)

*
ExoFlo (DB-001): Direct Biologics

*
MultiStem (HLCM051): Healios/Nobel Pharma

*
Remestemcel-L: Mesoblast

*
TP508: Chrysalis BioTherapeutics

*
Traumakine: Faron Pharmaceuticals

*
BIO-11006: BioMarck Pharmaceuticals

*
MultiStem: Athersys

*
Solnatide: Apeptico Forschung und Entwicklung GmbH

Discover more about therapies set to grab major Acute Respiratory Distress Syndrome market share @ Acute Respiratory Distress Syndrome Treatment Market [https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the Acute Respiratory Distress Syndrome Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Acute Respiratory Distress Syndrome Companies: Veru, Edesa Biotech/Light Chain Bio, Direct Biologics, Healios/Nobel Pharma, Mesoblast, Chrysalis BioTherapeutics, Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeutics, Meridigen Biotech Co., Ltd., Sage Therapeutics, Healios K.K., Chiesi Farmaceutici, Bayer, Altor BioScience, Faron Pharmaceuticals Ltd, AVM Biotechnology LLC, Amyndas Pharmaceuticals S.A., Kinevant Sciences GmbH, Eli Lilly and Company, Suntory Pharmaceutical, Alexion Pharmaceuticals, Laboratoire francais de Fractionnement et de Biotechnologies (LFB), Evgen Pharma, Dimerix Bioscience, Mylan, Vanda Pharmaceuticals, Kiniksa Pharmaceuticals Foresee Pharmaceuticals, Boehringer Ingelheim, Staidson (Beijing) Biopharmaceuticals, Biohaven Pharmaceuticals, Chimerix, Edesa Biotech, and others

*
Key Acute Respiratory Distress Syndrome Therapies: Sabizabulin (Veru-111), EB05 (paridiprubart), ExoFlo (DB-001), MultiStem (HLCM051), Remestemcel-L, TP508, Traumakine, BIO-11006, MultiStem, Solnatide, VERU-111, Tradipitant, FP-025, HLCM051(MultiStem), and others

*
Acute Respiratory Distress Syndrome Therapeutic Assessment: Acute Respiratory Distress Syndrome current marketed and Acute Respiratory Distress Syndrome emerging therapies

*
Acute Respiratory Distress Syndrome Market Dynamics: Acute Respiratory Distress Syndrome market drivers and Acute Respiratory Distress Syndrome market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Acute Respiratory Distress Syndrome Unmet Needs, KOL's views, Analyst's views, Acute Respiratory Distress Syndrome Market Access and Reimbursement

To know more about Acute Respiratory Distress Syndrome companies working in the treatment market, visit @ Acute Respiratory Distress Syndrome Clinical Trials and Treatment [https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Acute Respiratory Distress Syndrome Market Report Introduction

2. Executive Summary for Acute Respiratory Distress Syndrome

3. SWOT analysis of Acute Respiratory Distress Syndrome

4. Acute Respiratory Distress Syndrome Patient Share (%) Overview at a Glance

5. Acute Respiratory Distress Syndrome Market Overview at a Glance

6. Acute Respiratory Distress Syndrome Disease Background and Overview

7. Acute Respiratory Distress Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Acute Respiratory Distress Syndrome

9. Acute Respiratory Distress Syndrome Current Treatment and Medical Practices

10. Acute Respiratory Distress Syndrome Unmet Needs

11. Acute Respiratory Distress Syndrome Emerging Therapies

12. Acute Respiratory Distress Syndrome Market Outlook

13. Country-Wise Acute Respiratory Distress Syndrome Market Analysis (2020-2034)

14. Acute Respiratory Distress Syndrome Market Access and Reimbursement of Therapies

15. Acute Respiratory Distress Syndrome Market Drivers

16. Acute Respiratory Distress Syndrome Market Barriers

17. Acute Respiratory Distress Syndrome Appendix

18. Acute Respiratory Distress Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acute-respiratory-distress-syndrome-market-growth-to-accelerate-in-forecast-period-20242034-delveinsight-analyzes-veru-athersys-inc-histocell-bioxcellerator-altor-bioscience-cartesian]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.